Chikungunya virus infections among travellers returning to Spain, 2008 to 2014 by Fernández-García, M. D. et al.
1www.eurosurveillance.org
Surveillance and outbreak report 
Chikungunya virus infections among travellers 
returning to Spain, 2008 to 2014
MD Fernandez-Garcia 1 2 3 , M Bangert 1 3 4 5 , F de Ory ¹ , A Potente ¹ , L Hernandez ¹ , F Lasala ¹ , L Herrero ¹ , F Molero ¹ , A Negredo 
¹ , A Vázquez ¹ , T Minguito ¹ , P Balfagón ¹ , J de la Fuente ¹ , S Puente ⁶ , E Ramírez de Arellano ¹ , M Lago ⁶ , M Martinez 7 8 , J 
Gascón ⁷ , F Norman ⁹ , R Lopez-Velez ⁹ , E Sulleiro 10 11 , D Pou 11 , N Serre 11 , RF Roblas 12 , A Tenorio ¹ , L Franco 1 3 13 , MP Sanchez-
Seco 1 3 
1. Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain
2. Current affiliation: Institut Pasteur de Dakar, Dakar, Senegal
3. These authors contributed equally to this manuscript
4. Current affiliation: World Health Organization, Geneva, Switzerland
5. European Union Public Health Microbiology training programme (EUPHEM), European Centre for Disease Prevention and 
Control (ECDC), Stockholm, Sweden
6. Hospital Carlos III-La Paz, Madrid, Spain
7. ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, 
Spain
8. Department of Clinical Microbiology, Hospital Clínic, Barcelona, Spain
9. Hospital Ramon y Cajal, Madrid, Spain
10. Department of Microbiology, Hospital Universitari Vall d’Hebron, Barcelona, Spain
11.  Tropical Medicine and International Health Unit Drassanes-Vall d’Hebron, PROSICS Barcelona, Barcelona, Spain
12. Fundación Jimenez Diaz, Madrid, Spain
13. Current affiliation: Gorgas Memorial Institute, Panama City, Panama 
Correspondence: Leticia Franco (francolet@gmail.com)
Citation style for this article: 
Fernandez-Garcia MD, Bangert M, de Ory F, Potente A, Hernandez L, Lasala F, Herrero L, Molero F, Negredo A, Vázquez A, Minguito T, Balfagón P, de la Fuente J, 
Puente S, Ramírez de Arellano E, Lago M, Martinez M, Gascón J, Norman F, Lopez-Velez R, Sulleiro E, Pou D, Serre N, Roblas RF, Tenorio A, Franco L, Sanchez-Seco 
MP. Chikungunya virus infections among travellers returning to Spain, 2008 to 2014. Euro Surveill. 2016;21(36):pii=30336. DOI: http://dx.doi.org/10.2807/1560-
7917.ES.2016.21.36.30336
Article submitted on 26 August 2015 / accepted on 10 March 2016 / published on 08 September 2016
Since the first documented autochthonous transmis-
sion of chikungunya virus in the Caribbean island of 
Saint Martin in 2013, the infection has been reported 
within the Caribbean region as well as North, Central 
and South America. The risk of autochthonous trans-
mission of chikungunya virus becoming established 
in Spain may be elevated due to the large numbers of 
travellers returning to Spain from countries affected 
by the 2013 epidemic in the Caribbean and South 
America, as well as the existence of the Aedes albopic-
tus vector in certain parts of Spain. We retrospectively 
analysed the laboratory diagnostic database of the 
National Centre for Microbiology, Institute of Health 
Carlos III (CNM-ISCIII) from 2008 to 2014. During the 
study period, 264 confirmed cases, of 1,371 suspected 
cases, were diagnosed at the CNM-ISCIII. In 2014 
alone, there were 234 confirmed cases. The highest 
number of confirmed cases were reported from the 
Dominican Republic (n = 136), Venezuela (n = 30) and 
Haiti (n = 11). Six cases were viraemic in areas of Spain 
where the vector is present. This report highlights the 
need for integrated active case and vector surveillance 
in Spain and other parts of Europe where chikungunya 
virus may be introduced by returning travellers.
Introduction
Since the first outbreak in Tanzania in 1952, chikun-
gunya has been endemic in some parts of Africa, 
south-east Asia and in the Indian subcontinent [1]. In 
2013, however, the first documented autochthonous 
transmission of chikungunya virus was reported in the 
Caribbean island of Saint Martin [2] and since then the 
infection has spread quickly to other countries and ter-
ritories of the Caribbean as well as to North, Central 
and South America [2]. As at 31 December 2014 (the 
final day of our study), 24,682 confirmed autochtho-
nous cases and 1,118,763 suspected cases of chikun-
gunya in the Americas had been reported by the Pan 
American Health Organization (PAHO) [3]. A large 
majority of these suspected autochthonous cases (n 
= 802,714; 72%) were reported from the Caribbean, 
in particular from the Dominican Republic (539,099; 
67%).
A chikungunya outbreak in 2005 in Réunion, a French 
overseas department and region, affected 266,000 
people (ca 35% of the population), including 783 cases 
imported to metropolitan France [4]. During this out-
break, a mutation (A226V in the chikungunya virus E 
protein) that improved the replication in Aedes albop-
ictus was observed, giving rise to a new virus variant 
whose fitness in this mosquito was increased [5].
The transmission of chikungunya virus to humans 
occurs mainly through bite of infected Ae. aegypti or 
Ae. albopictus mosquitoes, which can also transmit 
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dengue virus. In Europe, Ae. albopictus is established 
primarily around the Mediterranean basin [6,7] and has 
been demonstrated to be competent for chikungunya 
virus transmission in this region [8]. This has resulted 
in locally acquired infections in Italy (Emilia Romagna 
region, 2007) as well as in France (Var and Montpellier, 
2010 and 2014 respectively) [9-11].
In Spain, despite the presence of Ae. albopictus in the 
eastern Mediterranean regions (Catalonia, Valencia, 
Murcia, Balearic Islands) [12] and recently in the south-
ern region of Andalusia [13] and in the Basque Country 
[14], no autochthonous transmission of chikungunya 
virus has been reported. However, the risk of autoch-
thonous transmission of chikungunya establishing in 
Spain may be elevated due to the large numbers of trav-
ellers returning to Spain from countries affected by the 
2013–14 epidemic in the Caribbean and South America 
[2], as well as the existence of the competent vector 
in certain parts of Spain. In order to further assess 
this risk and better understand the epidemiological 
and laboratory characteristics of imported chikungu-
nya cases, we retrospectively analysed the labora-
tory diagnostic database of the National Centre for 
Microbiology, Institute of Health Carlos III (CNM-ISCIII) 
from 2008 to 2014.
Methods
Case definition
The case definition used followed the guidelines pro-
vided by the Spanish Ministry of Health [15] and the 
European Centre for Disease Prevention and Control 
(ECDC) [16]. 
A suspected case was a patient meeting clinical criteria 
(acute onset of fever (> 38 °C) and severe arthralgia not 
explained by other medical conditions) and epidemio-
logical criteria (residing in or having visited epidemic 
or endemic areas). 
A confirmed case was a patient meeting the laboratory 
criteria, irrespective of the clinical presentation (with 
at least one of the following: virus isolation, presence 
of viral RNA, presence of virus-specific IgM antibodies 
in a single serum sample collected in acute or conva-
lescent stage, or fourfold rise in IgG titres in samples 
collected at least 15 days apart) [15]. Patients with chi-
kungunya virus or chikungunya viral RNA detected in 
serum were considered viraemic.
Serology and molecular analysis
The presence of IgM or IgG antibodies against chikun-
gunya virus was detected by indirect immunofluores-
cence (Euroimmun, Germany).
The presence of dengue virus IgG and IgM antibodies 
was detected using IgM capture ELISA and IgG indirect 
ELISA tests [17].
The presence of chikungunya viral RNA was detected 
by an in-house real-time reverse transcription-PCR 
(RT-PCR) and confirmed by two established PCR proto-
cols [18].
Dengue diagnostics
Dengue viral RNA was detected using RT-PCR [19]. 
Dengue nonstructural protein 1 antigen (NS1) was 
detected by enzyme immunoassay (Platelia Dengue 
NS1 Ag, Biorad).
Data used
All data from samples received for diagnosis and sur-
veillance of imported viral infections in the CNM-ISCIII 
between 1 January 2008 and 31 December 2014 were 
included in the study. Samples and data were codified 
with a unique ID to ensure the anonymity of patients.
We accessed the CNM-ISCIII database, in which infor-
mation was typically collected on sex, age, date of 
onset of symptoms, date of specimen collection, travel 
destination and hospitalisation. We also contacted 
Figure 1
Number of suspected and confirmed imported 
chikungunya cases by year and by month, Spain, 2008–14 
(suspected n = 1,371; confirmed n = 264)
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local health authorities and hospitals to retrieve 
information on travel destination. Samples included 
acute and convalescent sera. We used international 
travel statistics obtained from a 2014 World Tourism 
Organization report [20] to estimate incidence rates 
of chikungunya virus-infected travellers returning to 
Spain.
Results
Infections reported and patient characteristics
During the study period (1 January 2008 to 31 December 
2014), a total of 1,371 suspected chikungunya cases 
were identified (179 in 2008, 134 in 2009, 177 in 2010, 
129 in 2011, 93 in 2012, 87 in 2013 and 572 in 2014). The 
most frequently reported reasons for travel were work 
(aid workers, missionaries, others), visiting friends and 
relatives and tourism. In 2008–13, the median number 
of suspected cases was 131 (range: 87–179). Of the 
1,371 suspected cases in 2008–14, 42% (n = 572) were 
reported in 2014 alone.
A total of 264 (19%) suspected cases were laboratory 
confirmed by CNM-ISCIII during the study period. Of 
the confirmed cases, the majority were female (n = 
159; 60%), with a median age of 43 years (range: 1–93). 
The number of suspected and confirmed imported 
cases from 2008 to 2014 in Spain is shown in Figure 
1A. During 2008–13, 30 imported chikungunya cases 
were laboratory confirmed (6 in 2008, 4 in 2009, 11 in 
2010, 5 in 2011, 1 in 2012, 3 in 2013) with a median of 
5 (range: 1–11) cases identified per year, while in 2014 
there were 234 confirmed imported cases. The ratio 
of confirmed to suspected cases shifted from 1:28 in 
2008–2013 to 1:3 in 2014. The distribution of imported 
cases by month during our study period in Spain shows 
that the number of confirmed and suspected cases 
reached its peak during July (Figure 1B).
Travel history
The travel history of the patients is detailed in Table 
1. Between 2008 and 2013, the travel destination 
was known for 19 of the 30 confirmed cases: 17 cases 
had travelled to Asia (Indonesia (n = 5), India (n = 5), 
Myanmar (n = 2), Thailand (n = 1), Philippines, (n = 1), 
other Asian countries not specified (n = 3)) and two 
cases had travelled to Africa (Cameroon and Equatorial 
Guinea). Of the 234 cases in 2014, the travel history 
of 220 patients (94%) was known: 154 cases (70%) 
reported having visited the Caribbean during the 
incubation period [16], 59 cases had visited Central 
and South America (Venezuela, Colombia, Mexico, 
Nicaragua, Peru, El Salvador, Panama), five had visited 
Africa (Angola, Madagascar, Equatorial Guinea, and 
Figure 2
Geographical spread of confirmed imported chikungunya cases (n = 264) and presence of chikungunya virus vector Aedes 
albopictus in autonomous regions of Spain, 2008–14
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Mozambique) and two had visited Asia (India, unspeci-
fied). No autochthonous infections acquired in Spain 
were identified or reported by the health authorities.
The incidence rates of chikungunya in travellers world-
wide returning to Spain are shown in Table 1. The 
highest incidence rate in 2014 was seen in travellers 
returning from Venezuela, with 4.92 cases per 100,000 
travellers, followed by those who had travelled to 
Haiti (3.46/100,000) and the Dominican Republic 
(3.08/100,000). In contrast, during 2008–13, the high-
est incidence rate was in travellers returning from 
Myanmar, with 0.36 cases per 100,000 travellers.
Information about reason for travel was available for 
a limited number of suspected cases in 2014 (n = 66). 
Among those 66 suspected cases, the most frequently 
reported reasons for travel were visiting friends and 
relatives (n = 27), tourism (n = 25) and work (n = 14; aid 
workers, missionaries, others).
Region of notification and presence of vector
Overall, 120 hospitals in all Spanish regions referred 
samples to the CNM-ISCIII during the study period. 
Of the 264 cases confirmed between 2008 and 2014, 
Madrid and Catalonia had the largest number of notifi-
cations (150 (57%) and 44 (17%), respectively). A total 
Table 1
Number of confirmed chikungunya cases (n = 264) and incidence rate of chikungunya among travellers returning to Spain, 
by travel destination, 2008–2014
Travel destinations – 
countries and territories
Mean annual number 
of travellers from Spain 
during 2008–13a
2008–13 2014
Number of 
cases
Incidence rate per 100,000 
travellers arriving in Spain
Number of 
cases
Incidence rate per 100,000 
travellers arriving in Spain
Americas
Venezuela 610,333 0 0 30 4.92
Haiti 317,666 0 0 11 3.46
Dominican Republic 4,421,000 0 0 136 3.08
Guadeloupe 405,000 0 0 2 0.49
Martinique 487,000 0 0 1 0.21
Colombia 2,200,000 0 0 3 0.14
Dominica 77,250 0 0 1 1.29
Puerto Rico 3,125,750 0 0 3 0.10
Nicaragua 1,083,000 0 0 1 0.09
El Salvador 1,196,000 0 0 1 0.08
Panama 1,515,250 0 0 1 0.07
Peru 2,581,000 0 0 1 0.04
Americas (unspecified, but 
excluded North America) 57,849,000 0 0 21 0.04
Mexico 23,365,000 0 0 1 0.00
Africa
Mozambique 1,911,000 0 0 1 0.05
Madagascar 218,250 0 0 1 0.46
Angola 478,000 0 0 2 0.42
Cameroon 664,666 1 0.15 0 0
Equatorial Guineab No data 1 NC 1 NC
Asia
India 6,377,750 5 0.07 1 0.02
Asia (unspecified) 235,587,000 3 0.00 1 0
Indonesia 7,874,750 5 0.06 0 0
Myanmar 54,875 2 0.36 0 0
Thailand 21,016,750 1 0.00 0 0
Philippines 4,097,750 1 0.02 0 0
No travel destination specified
Cases with missing data NA 11 NA 14 NA
Total number of cases NA 30 NA 234 NA
NA: not applicable; NC: not calculated, as no denominator data.
a Source: [20] for data from 2008 to 2012 and [45] for data from 2009 to 2013. At the time of analysis, traveller data were not available for 
2014. 
b Traveller data were not available for Equatorial Guinea for 2008–13.
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of 66 of the cases (25%) were reported in regions where 
Ae. albopictus is present (Catalonia, Autonomous 
Community of Valencia, Basque Country, Murcia, 
Balearic Islands, and since 2013 southern Andalusia) 
(Figure 2). Of these 66 cases, six were viraemic (PCR 
positive) when presenting to clinicians in Spain. 
In 2014, during the active period of Ae. albopictus 
in Spain (May–October), we confirmed a total of 33 
imported cases in regions with vector presence, three 
of whom were viraemic when presenting to clinicians 
in Spain. 
Serological diagnostics
Of the 33 confirmed imported cases in regions in which 
Ae. albopictus was present, 30 had anti-chikungunya 
virus IgM antibodies, suggesting recent infection.
Serology was performed on 1,147 of the 1,371 (84%) 
suspected imported cases. Of the 1,147 tested, 235 
(20%) were positive for IgM. Of the 235 IgM-positive 
samples, 11 (5%) also tested positive by the molecular 
methods described. 
From 36 IgM-positive imported cases with known date 
of symptoms onset, samples were collected within 0 to 
37 days after onset (median: 7 days).
Paired serum samples were available for 37 confirmed 
cases, where the time elapsed between the first and 
second samples ranged from 2 to 210 days. The results 
of the IgM and IgG assays are shown in Table 2. The 
time taken for an initially positive IgM test to become 
negative ranged from 93 to 181 days in our study. 
Among cases for whom the first sample was IgG posi-
tive, some remained IgG positive for up to 210 days, 
when the second sample was taken. Of 37 paired serum 
samples, 15 demonstrated seroconversion within 14 to 
60 days.
Molecular diagnostics
Molecular diagnosis was carried out for samples from 
481 (35%) of the 1,371 suspected cases: viral genome 
was detected by RT-PCR in 39 (8%) of the 481 tested. 
Of the 39 patients with a chikungunya virus-positive 
PCR, 11 had a known date of symptom. The samples 
were collected 0–3 days after symptom onset except 
for one, which was collected after six days. 
Of the 235 patients whose infection was confirmed by 
IgM, 86 were negative by PCR. For these 86 patients, 
the median time from onset of symptoms to sample 
collection was four days (range: 0–35).
Concurrent infection
Of the 1,371 suspected chikungunya cases reported 
during the study period, 817 were also tested for the 
presence of anti-dengue virus IgG and IgM antibod-
ies, dengue RNA and/or dengue nonstructural protein 1 
antigen (NS1). In 2014, 41% (234/572) of the suspected 
chikungunya cases were tested for dengue virus infec-
tion while in the rest of the study period (2008–13), 
73% (583/799) of the suspected chikungunya cases 
were tested for dengue virus infection. Dengue RNA, 
NS1 and/or anti-dengue virus IgM antibodies were 
found in 116 of the 1,371 suspected chikungunya cases. 
During 2008–13, a total of 87 imported dengue cases 
were laboratory confirmed (9 in 2008, 13 in 2009, 28 in 
2010, 9 in 2011, 12 in 2012, 16 in 2013); in 2014, there 
were 29 confirmed imported dengue cases. The dis-
tribution of dengue imported cases by month in 2014 
showed that the number of confirmed cases reached its 
peak during August (data not shown). A total of 13/29 
confirmed dengue cases in August 2014 reported hav-
ing visited the Americas. 
Of the 116 dengue cases, five were also confirmed as 
positive for chikungunya virus, one in 2010 and four in 
2014. Of these five, three had anti-dengue virus and 
Table 2
Indirect immunofluorescence results and interval between the dates the first and second samples were taken, for 
convalescent paired samples from 37 confirmed cases, Spain, 2008–14
Indirect immunofluorescence results
Number of samples Mean time in days
a (range) between the dates the first and 
second samples were taken, post symptom onsetFirst sample Second sample
IgM
 Pos Pos 17 43 (7–79)
Neg Pos 4 22.5 (16–29)
 Neg Neg 4 117 (53–181
IgG
Pos Pos 17 108 (6–210)
Neg Pos 15 38 (16–60)
Pos Neg 1 58b (NA)
NA: not applicable; Neg: negative; Pos: positive. 
a Unless otherwise specified. 
b The second sample was taken 58 days after symptom onset. The date the first sample was taken was not available.
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anti-chikungunya virus IgM, one had anti-dengue virus 
IgM and chikungunya viral RNA, and one had dengue 
viral RNA and chikungunya viral RNA. The coinfected 
patients in 2014 had returned from Venezuela (n = 2) 
and the Dominican Republic (n = 2). The patient coin-
fected in 2010 had returned from the Philippines (Table 
3).
Discussion
We have described a 7.8 fold increase in the number of 
imported chikungunya virus infections from 2008–13 
(30 cases) to 2014 (234 cases) in Spain, with the num-
ber in 2014 being the highest recorded in the country. 
Every year since 2006, imported chikungunya cases 
have been identified among travellers returning to 
Spain. During 2006 to 2007, 29 laboratory-confirmed 
imported cases were diagnosed among a cohort of 
308 travellers with symptoms compatible with acute 
or recent chikungunya virus infection on their return to 
Spain [21]. The majority of these cases (n = 20) had vis-
ited India or the Indian Ocean Islands. Similarly, dur-
ing 2008 to 2013, most imported cases (17/19) arrived 
from Asia. As a result of an ongoing outbreak in the 
Americas, with more than 780,000 suspected cases by 
31 October 2014 [22], however, the majority of cases 
imported to Spain in 2014 were from the Caribbean 
and northern parts of South America [23], demonstrat-
ing the potential of this large chikungunya outbreak to 
affect Spain.
The Caribbean is a popular travel destination for 
Spanish travellers during the spring and summer 
months. It is also a destination for migrants living in 
Spain, who travel back home to visit friends and rela-
tives, as shown by the large proportion of chikungunya 
cases in our study who had visited friends and rela-
tives (27/66). Spain has a dynamic population of Latin 
American and Caribbean immigrants with permanent 
residency in Spain who frequently travel to their coun-
try of origin. Immigrants from the Caribbean, espe-
cially the Dominican Republic, have represented the 
one of the largest proportion of immigrants in Spain in 
recent decades and a continued growth of Dominican 
immigration is predicted for the future [24]. This corre-
lates with the high number of confirmed chikungunya 
cases from the Dominican Republic (136/264) seen in 
our study. Furthermore, migrants visiting friends and 
relatives are less likely than tourists to seek travel 
health advice, and therefore to take preventive meas-
ures during their stay, representing an important gate-
way for the entry of chikungunya virus in Europe [25]. 
This challenge requires appropriate countermeasures 
such as targeted guidance to these groups of travellers 
at risk and early screening.
During 2015, however, the virus spread from the 
Caribbean to South and Central America, and more 
countries have become affected. The virus spread in 
Colombia, Venezuela, Brazil and other South American 
countries during the summer of 2015. In Brazil, where 
in 2014 a total of 3,657 cases distributed in eight 
municipalities were reported, in 2015 the number of 
cases increased more than fivefold, to 20,661 cases in 
84 municipalities, mainly in north-east and south-west 
states [26].
Appropriate surveillance and investigation of imported 
chikungunya cases could also aid in understanding 
better the epidemiological and virological dynamics 
of the outbreak in the Caribbean and Latin American 
countries. Returning travellers can serve as indirect 
sentinels to monitor the geographical spread of the 
outbreak in the Americas. For example, in our study 
52% of imported cases came from the Dominican 
Republic, in line with PAHO s´ report in October 2014 
that showed 62% of cases in the Americas stem from 
this country [22]. Similarly, in late 2014, 13% of chi-
kungunya virus-infected travellers were returning from 
Venezuela, around the time the country was facing a 
large re-emergence of vector-borne diseases [27]. If we 
look in 2015 for chikungunya cases in Spain imported 
from Venezuela, the percentage would probably be 
larger due to the large epidemic there. 
Sharing of data gained through analysis of return-
ing travellers could support countries where no or 
scarce data on chikungunya have been reported. In 
our study, for example, we saw an imported case 
from Mozambique, a country that only recently dem-
onstrated circulation of chikungunya virus [28]. We 
also saw cases in travellers returning from Colombia, 
El Salvador and Nicaragua, which have reported local 
Table 3
Dengue virus and chikungunya virus laboratory results from coinfected confirmed imported cases, Spain, 2008–14 (n = 5)
Case Confirmed dengue
Confirmed chikungunya
Travel destination Year
IgM IgM plus PCR PCR
1
IgM positive
Pos Neg Neg Venezuela 2014
2 Pos Neg Neg Philippines 2010
3 Pos Neg Neg Dominican Republic 2014
4 Neg Neg Pos Dominican Republic 2014
5 IgM and PCR positive Neg Neg Pos Venezuela 2014
Neg: negative; Pos: positive.
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transmission, and from Panama, which had reported 
imported cases in 2014 [3,29]. While this can serve 
as an indication, using travel information alone is not 
sufficient to definitively determine the country source 
of infection as travel is seasonal to most destinations 
and the epidemic may have been introduced before 
infected travellers returned.
Although the chikungunya outbreak in the Caribbean 
has led to an increase in the number of cases in Spain, 
enhanced surveillance may have also contributed to 
the rise. Chikungunya was classified a notifiable dis-
ease in 2013 by the Consejo Interterritorial del Sistema 
Nacional de Salud and became law in 2015, after our 
study period [30,31]. This may have led to greater 
awareness among patients and physicians, resulting 
in better ascertainment of suspected cases. Before 
the outbreak in the Caribbean, 1 in 28 suspected chi-
kungunya cases were confirmed positive in the ISCIII 
whereas in 2014, the ratio was 1 in 3 (confirmed vs 
suspected cases). In 2008–13, of the 799 cases noti-
fied only 30 were confirmed, whereas in 2014, 234 of 
572 notified cases were confirmed. Similarly, in south-
eastern France, an increase in the number of suspected 
cases was noted in 2010 due to enhanced surveillance 
for chikungunya implemented after autochthonous chi-
kungunya transmission was reported [10].
Although autochthonous transmission of chikungunya 
has been documented in south-eastern France in 2010 
and 2014 [8,10] as well as in Italy in 2007 [9], Spain 
has not reported local transmission of chikungunya 
virus, despite the presence of Ae. albopictus mosqui-
toes in the country [32]. Chikungunya virus strains with 
the A226V viral mutation have not yet been described 
in America, as the circulating genotype is the Asian 
one and not the East/Central/South African (ECSA) 
genotype, in which the mutation arose [5]. This muta-
tion should be considered in risk assessments of local 
transmission in Spain. Our data show that most travel-
lers returned to Spain during the warm months of June 
to September, coinciding with the period of activity 
for Ae. albopictus (May–October). In 2014, the highest 
number of confirmed imported cases of chikungunya 
were in areas in which the vector was present (n = 66; 
Catalonia, Autonomous Community of Valencia, Murcia, 
Basque Country, Balearic Islands and Andalusia). 
Importantly, six of these 66 confirmed cases were 
positive by PCR. Such viraemic travellers are potential 
disseminators of the virus through bites of vectors, or 
by donating blood [33]. The ability of infected vectors 
to effectively overwinter until the next hot season fur-
ther adds to the importance of imported chikungunya 
[34]. Considering that autochthonous transmission in 
France in 2010 occurred following importation of only 
two cases of chikungunya, the high number of infected 
travellers returning to Spain highlights the increased 
risk of autochthonous transmission becoming estab-
lished. It is important to note that, to date, countries 
affected by localised outbreaks in the EU have been 
able to contain further spread of the disease [10,35].
Serological diagnosis can be performed by detection 
of specific IgM antibodies in serum from four to five 
days after the onset of symptoms, or a fourfold rise 
in chikungunya- specific IgG antibody titre in a paired 
serum sample. Chikungunya-specific IgM can persist 
for months, in particular in patients with persistent 
arthralgia [36]. The reported sensitivity of the com-
mercial Immunofluorescence test used for detection of 
chikungunya-specific IgM has been 98.3%, with a sen-
sitivity of 96.9% [37]. The specificity and sensitivity 
for the detection of IgG is 100.0% and 95.4%, respec-
tively [37]. In our study, we observed that IgM can be 
detected from a median of seven days after onset of 
symptoms and that IgG can be detected from 16 days 
after the first sample is taken. This highlights that if 
specimens are collected very early in the course of the 
illness and tested only for IgM antibodies, serological 
diagnostic testing may not detect cases. In convales-
cent samples, we observed that IgM can persist up to 
79 days. This should be taken into consideration when 
sampling and testing for chikungunya virus in return-
ing travellers. Further study is also merited as com-
plete case information for this analysis was available 
only for a limited subset of cases.
As chikungunya virus infection has similar symptoms 
as dengue and both viruses can circulate in the same 
area, chikungunya fever has often been mistaken for 
dengue. Confirmed dengue imported cases among trav-
ellers seen in our study support the suspicion of dual 
endemic circulation of dengue and chikungunya viruses 
in the Caribbean. Coinfections have been reported in 
Saint Martin, where 2.8% of chikungunya cases were 
reported as dengue coinfections in December 2013 
to January 2014 [38]. In 2010, south-eastern France 
reported the concomitant emergence of dengue and 
chikungunya viruses, with two autochthonous infec-
tions reported for each [10,35]. Here we report five 
coinfections, four occurring in 2014 and one in 2010. 
Coinfections in travellers returning to Europe from the 
Indian Ocean Region in 2006 have been reported [39]. 
In addition, imported cases of Mayaro virus infection, 
an American alphavirus, were described in Germany in 
2013 [40], France in 2010 [41] and the Netherlands in 
2008 [42]. An imported case of O’nyong nyong virus 
infection, an African alphavirus, was described in 
Germany in 2013 [43]. Differential diagnosis of alphavi-
ruses is therefore important and physicians should 
familiarise themselves with their clinical presentation.
The importance of coinfection is further highlighted as 
Ae. albopictus is also a recognised vector with compe-
tence and capacity to transmit dengue virus. With the 
increasing spread of Ae. albopictus in southern Europe, 
the risk of the establishment of these two arboviruses 
in Europe has also increased [44]. Continued aware-
ness of other emerging diseases is needed to ensure 
rapid detection and control. The implementation of 
a strategic national surveillance system adapted to 
the early detection of both chikungunya and dengue, 
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combined with vector monitoring systems, is urgently 
needed.
Considering the intense international traffic between 
Spain and countries affected by the 2013–14 chikun-
gunya outbreak, as well as immigration and the dis-
tribution of competent vectors, chikungunya virus is 
becoming a threat to Spain and neighbouring coun-
tries. This report highlights the need for integrated 
active case and vector surveillance in Spain and other 
parts of Europe where the virus may be introduced by 
returning travellers. We furthermore highlight our expe-
riences with diagnosing samples from returning travel-
lers and how they can be used to indirectly monitor the 
spread of the outbreak in the Americas. An outbreak 
of chikungunya in Spain could have a considerable 
impact on public health, the safety of blood donation 
supplies and on tourism. With the 2013–14 outbreak in 
the Americas, the number of chikungunya cases among 
travellers returning to Spain from affected areas is 
likely to continue to increase, especially in the sum-
mer season in Spain. Mediterranean countries should 
strengthen preparedness for the re-emergence and/or 
reintroduction of chikungunya virus and other Aedes-
transmitted diseases, especially in regions where Ae. 
albopictus is present or could become established.
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